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Abstract
In patients who are HIV infected, hepatitis B virus (HBV) infection is an important co-morbid-
ity. However, antiretroviral options for HIV/HBV co-infected children are limited and, at the
time of this study, only included lamivudine. These children may remain on this regimen for
many years until late adolescence. They are at high risk of developing HBV drug resistance
and uncontrolled HBV disease. The aim of this study was to characterize HBV infection in
HIV/HBV co-infected children. Known HIV-infected/HBsAg-positive children, previously
exposed to lamivudine monotherapy against HBV, and their mothers were recruited at the
Katutura Hospital paediatric HIV clinic in Windhoek, Namibia. Dried blood spot and serum
samples were collected for HBV characterization and serological testing, respectively. Fif-
teen children and six mothers participated in the study. Eight of the 15 children (53.3%)
tested HBV DNA positive; all eight children were on lamivudine-based ART. Lamivudine-
associated resistance variants, together with immune escape mutants in the surface gene,
were identified in all eight children. Resistance mutations included rtL80I, rtV173L, rtL180M,
rtM204I/V and the overlapping sE164D, sW182*, sI195M and sW196LS variants. HBV
strains belonged to genotypes E (6/8, 75%) and D3 (2/8, 25%). Further analysis of the HBV
core promoter region revealed mutations associated with reduced expression of HBeAg pro-
tein and hepatocarcinogenesis. All six mothers, on HBV-active ART containing tenofovir
and lamivudine, tested HBV DNA negative. This study confirms the importance of screening
HIV-infected children for HBV and ensuring equity of drug access to effective HBV treatment
if co-infected.
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Introduction
The effects of hepatitis B virus (HBV) infection, which is endemic in Africa, are amplified in
the context of populations where HIV prevalence is high [1]. Liver disease caused by chronic
viral hepatitis infection is a leading cause of death in HIV-infected individuals [2, 3]. Whilst
HIV infection alone has been associated with liver fibrosis [4]. Poor immune control and
higher HBV viral loads in the HIV/HBV co-infected individual, may increase susceptibility to
liver damage. Furthermore, mutations in specific HBV genomic regions such as pre-S and
basal core promoter (BCP) are associated with an increased risk of liver cirrhosis and hepato-
cellular carcinoma (HCC) [5, 6]. The prevalence of these variants may be higher in HIV/HBV
co-infected than HBV mono-infected individuals [7] and have been shown to accumulate over
time [8].
HIV first-line antiretroviral therapy (ART) includes lamivudine in children <10 years and
tenofovir (TDF) in those >10 years [9]. Due to the lack of ART options for children <10
years, many HIV/HBV co-infected children are exposed to lamivudine monotherapy for HBV
treatment for many years. Long-term lamivudine monotherapy is associated with the evolu-
tion of HBV resistance [10], leading to uncontrolled HBV replication. This is an important
risk factor for developing the complications of HBV infection [11]. Selecting mutant viruses
resistant to nucleos(t)ide antiviral drugs in the viral polymerase gene may cause changes in the
surface gene, resulting in loss of vaccine protection [12].
Limited data are available on the prevalence of HBV infection in children in sub-Saharan
Africa (SSA). Previous studies have revealed HIV/HBV co-infection prevalence rates of 0.8%
in South Africa [13], and 10.4% in Zambia [14]. A 2012 study revealed an HBsAg prevalence
of 8.7% among 1057 HIV-infected children < 18 years of age in Northern Namibia; a 6.5%
HBsAg prevalence was observed among those aged less than one year [15]. Neither the evolu-
tion of liver disease nor the molecular markers associated with liver damage in the African
HIV/HBV co-infected child are well understood. This study aimed to characterize HBV in
lamivudine-experienced HIV/HBV co-infected children and to assess their liver health.
Materials and methods
Ethical considerations
Ethical approval for this cross-sectional cohort study was obtained from the Health Research
Ethics Committee at Stellenbosch University (Reference number: N13/02/022) and the
Namibian Ministry of Health and Social Services. Assent was obtained from children enrolled
in the study. Written informed consent was also obtained from mothers or legal guardians
attending with these children.
Study population
HIV-infected patients are screened for HBV at enrolment in HIV care in Namibia. Known
HIV/HBV co-infected children and adolescents <18 years, exposed to lamivudine monother-
apy for HBV, attending the Katutura Hospital paediatric HIV clinic in Windhoek were invited
to take part in the study.
HBV serology and molecular testing
Paediatric HBsAg status was confirmed using the Murex GE 34/36 Surface Antigen kit (Dia-
sorin, Italy) on serum samples. Confirmed HBsAg-positive samples were analysed for anti-
HBc (total), HBeAg and anti-HBe by the anti-HBc and the HBeAg/anti-HBe Diasorin kits.
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Paediatric HBV DNA levels were determined using dried blood spots (DBS) on the auto-
mated COBAS1 AmpliPrep/COBAS1 TaqMan1HBV test V2.0 (Roche Diagnostics, Swit-
zerland) (lower limit of quantification = 1000 IU/ml using one DBS sample). One DBS sample
was eluted overnight at room temperature into a 1000 μl volume of pre-extraction buffer; from
this, viral DNA was extracted and amplified by the automated system.
HBV genotyping and mutation analysis
HBV DNA positive samples identified by the COBAS1 AmpliPrep/COBAS1 TaqMan1
HBV test V2.0 were further analysed for Sanger Sequencing and genotyping. Viral DNA was
extracted from these samples using the QIAamp1MinElute1 Virus Spin kit (QIAGEN, Ger-
many), after elution of DBS into 500 μl 1xPBS/0.05% Tween 20/0.08% sodium azide elution
buffer at room temperature [16]. Genomic amplification and sequencing of HBV pol/surf,
core promoter (CP) and precore (Pre-C) regions were performed as previously described [17].
Sequence chromatograms were edited, and consensus sequences were generated for each
genomic region and sample. Consensus sequences (Genbank accession numbers MN651971 –
MN651986) were submitted to the National Library of Medicine HBV Genotyping tool
(http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi) and the Stanford University
HBV sequencing tool (https://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html)
for the analysis of genomic variants.
Liver health assessment
Aspartate aminotransferase (AST) and platelet count were measured using the Architect c8000
(Abbott Laboratories, USA) and ABX Pentra XL80 (Horiba, Japan), respectively, for Aspartate
aminotransferase to platelet ratio (APRI) scores calculations. An APRI score> 0.5 was sugges-
tive of liver damage [18, 19].
Results
Study population
Between September 2014 and May 2015, 15 children known to be HIV/HBV co-infected
(range: 8–19 years old) were recruited. Three children (aged 17–19 years) were receiving TDF-
containing ART while 11 were on lamivudine-containing ART at enrolment. All 14 children
had been previously exposed to lamivudine monotherapy for HBV. The treatment history of
one patient was unknown.
HBV genotyping and mutation analysis
Eight children (8/15; 53.3%) had detectable HBV DNA levels (Table 1). All were on lamivu-
dine-based ART with full suppression of HIV replication. HBV strains grouped with genotype
E (6/8; 75%) and sub-genotype D3 (2/8; 25%). Amino acid changes including rtL80I, rtV173L,
rtL180M, rtV191I and rtM204I/V in the reverse transcriptase (RT) region of the pol gene, and
sE164D, sW182�, sI195M and sW196LS in the overlapping small HBsAg (SHB) region were
identified in all eight children. Additional substitutions were observed in the upper regulatory
region (URR) and BCP regions: patient 2C carried the HBV URR mutant G1728A and BCP
mutant G1764T/C1766G, and HBV from patients 6C and 7C carried BCP T1768A and URR
C1678T mutants, respectively. Pre-C genomic changes were found in three samples: G1862T
in sample 2C, and mixed populations of stop codon G1896A mutant and wild-type virus
(W28�W) in samples 3C and 6C.
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HBV serology
Ten of 15 paediatric samples were of adequate volume for HBV serological testing. All were
reactive for HBsAg and anti-HBc (total). Seven (7/10; 70%) HBsAg-positive samples had
detectable HBeAg, but anti-HBe not detected; three (3/10; 30%) did not have detectable
HBeAg, of which one was anti-HBe not detected and two were anti-HBe detected.
Liver health assessment
APRI scores were available for nine children. One HBV DNA positive child had an APRI score
of 0.713 (Table 1), the other 8 were<0.5.
Discussion
This study reports active HBV replication in 53.3% (8/15) HBV/HIV coinfected children in a
paediatric cohort from Windhoek, Namibia. All HBV DNA positive children had lamivudine
drug-associated HBV mutations. To our knowledge, this is the first report on the molecular
characterization of HBV in paediatric HIV/HBV co-infection in Africa.
Resistance to lamivudine is best recognized in association with the rtM204V/I mutation
[20, 21], which is also associated with decreased viral replication fitness [20], leading to the
subsequent selection of the compensatory mutants rtL180M, rtV173L, and rtL80I/V [22, 23].
The rtL80I mutant was most often found in presence of rtM204I as opposed to rtM204V, and
most prevalent among genotype D strains; as has been previously reported [23, 24]. Lamivu-
dine resistance mutations detected in the RT region resulted in sE164D, sI195M, and sW196L/
S changes in the surface gene. These are associated with reduced epitope-antibody binding, a
characteristic of viral immune evasion [12]. Selection of the sW182 stop codon (sW182�) arose
Table 1. Serology and molecular analysis data of eight HIV and HBV DNA positive children and adolescents.
Patient ID 2C 3C 6C 7C 8C 10C 13C 17C
Childhood HBV
vaccination
No No No No No No No No
ART regimen at
recruitment






APRI 0.713 0.481 0.330 0.321 NA 0.249 NA NA
HBsAg Positive Positive Positive Positive Positive Positive Positive NA
HBeAg Positive Positive Positive Positive Positive Positive Positive NA
Anti-HBe Negative Negative Negative Negative Negative Negative Negative NA
Anti-HBc (total) Positive Positive Positive Positive Positive Positive Positive NA
HBV DNA (log10
IU/ml)
7.11 7.48 6.86 6.23 7.30 7.64 7.29 6.68
HBV genotype E E E E D3 E E D3
















SHB mutations W182�, I195M E164D, I195M E164D, I195M I195M E164D E164D, I195M E164D, I195M W196L
Pre-core mutations G1862T G1896A/G G1896A/G None None None None None
BCP mutations G1728A, G1764T/
C1766G
None T1768A C1678T None None None None
ID: Identification; C: Child; HBV: hepatitis B virus; ART: Antiretroviral therapy; 3TC: Lamivudine; ABC: Abacavir; AZT: Zidovudine; EFV: Efavirenz; LPVr: Ritonavir-
boosted Lopinavir; NVP: Nevirapine; APRI: Aspartate aminotransferase to platelet ratio; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B envelope antigen; Anti-
HBe: antibody to hepatitis B envelope antigen; Anti-HBc: antibody to hepatitis B core antigen; DNA: Deoxyribonucleic acid; IU/ml: International Units per millilitre;
NA: not available; RT: reverse transcriptase, SHB: small hepatitis B surface antigen, BCP: basal core promoter.
https://doi.org/10.1371/journal.pone.0238839.t001
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from rtV191I. sW182� causes termination in the SHB gene, leading to intracellular accumula-
tion of HBsAg protein [25]; which may increase apoptosis of hepatocytes, potentially driving
hepatocarcinogenesis [25]. The presence of this variant in patient 2C, who also had an APRI
score of 0.713, is in keeping with reports of liver damage associated with this mutation [26]. The
risk of liver cirrhosis and HCC may also be increased in HBV-infected patients carrying BCP/
Pre-C mutations, which we identified in four children. The Pre-C stop codon G1896A (W28�)
mutation, observed in two children, interrupts HBeAg production [27]. The presence of both
W28� and wild-type virus (W28�W) explained the HBeAg positive status noted in these two
patients. It suggests the predominance of the wild-type virus over the mutant. The G1764T/
C1766G BCP double mutation is enriched among cirrhotic patients [28, 29], and combined
core mutations are more common in children with liver cirrhosis [30]. The accumulation of
these mutants may predispose these children to severe liver disease later in life [30]. The risk of
liver disease is supported by the finding of abnormal levels of biochemical markers of liver
health. The APRI score was successfully determined in nine children, of whom one (patient 2C)
presented with an abnormal score of 0.713. This was marginally elevated above the normal
value of 0.5. Elevated APRI scores among HIV/HBV co-infected children have previously been
reported elsewhere and identified as a predictor of liver disease in this population [19]. Though
the diagnostic sensitivity of APRI to identify liver fibrosis is relatively low (reported to be
around 47% [18]), it is worth noting that this patient also harboured HBV mutations associated
with severe liver disease including sW182� and BCP G1764T/C1766G, and presented with a
HBeAg positive status and high viraemia; these are known independent risk factors for the
development of liver cirrhosis and HCC [31, 32]. The limitations of accessing liver biopsies in
children and the poor access to transient elastography in this setting supports the notion that
further research into non-invasive markers of liver fibrosis in children is warranted.
Controlling HBV replication is crucial for preventing liver damage, hence the necessity for
effective ART in paediatric HIV/HBV co-infection. TDF or entecavir (ETV) are the preferred
drugs to treat HBV [33]. At the time of this study, Namibian HIV ART guidelines recom-
mended TDF in children older than ten years and weighing >35 kg [34]. These guidelines
have been updated to prescribing TDF in children older than two years of age and weighing
�17 kg [35], but paediatric TDF formulations have not been procured. Although decreased
susceptibility to ETV may be expected in presence of HBV rtM204V and rtL180M mutants
[36], doubling the dose of ETV overcomes the effects of these two mutations [37]. TDF has
activity against lamivudine-drug resistant HBV [38, 39]. However, neither ETV nor paediatric
TDF formulations are easily accessible in SSA. Co-formulated with elvitegravir, cobicistat, and
emtricitabine, tenofovir alafenamide (TAF) has demonstrated effectiveness and safety in HIV-
infected children [40] and may potentially be used for treating paediatric HIV/HBV co-infec-
tion. The drug is FDA-approved for children older than six years. Week 48 efficacy and safety
data from an ongoing clinical trial in HIV-infected children suggest the potential use of the
adult dose bictegravir, emtricitabine, and TAF for treating HIV/HBV co-infection in children
older than six years and weighing� 25kg [41]. ART regimens and formulations for children
younger than six years need to be explored.
Three children (5C, 9C, and 17C), aged 18, 19 and 17 years old respectively, were treated
with TDF at enrolment. Treatment with TDF was subsequent to two, seven and nine years of
previous exposure to lamivudine monotherapy against HBV, respectively. Having been on a
TDF-containing ART regimen for one, three and four years respectively, these children had
undetectable HBV viral load at HBV testing. Due to the cross-sectional nature of this study,
samples taken prior to TDF initiation were not available to determine prior existence of lami-
vudine-associated drug resistance mutations. Tenofovir therapy was the likely reason for the
suppressed HBV viral load.
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This study has identified children who require optimization of their antiviral treatment for
the control of HBV infection. However, detailed imaging including ultrasonography and elas-
tography would have provided greater breadth of data to better understand liver health in this
cohort. The limitation of this study is the small sample size. This study merely serves to high-
light the potential problems of HBV monotherapy where there is no access to TDF or other
more potent HBV acting agents in HIV/HBV co-infected children. Larger studies are needed
to ascertain the prevalence of HIV/HBV associated liver disease and importantly to determine
access to potent HBV active agents for young children.
Conclusion
HBV/HIV co-infected children, exposed to lamivudine monotherapy, are at risk of carrying
scarred HBV, and developing clinically significant liver disease. The diagnosis and optimized
treatment of paediatric HIV/HBV co-infection, including access to paediatric TDF formula-
tions, should be a priority. Advocacy and funding to provide safe and effective therapy for chil-
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